AXIM Biotech Holds Bi-Annual Board Meeting in New York City on July 8

NEW YORK, July 12, 2017 -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it held its bi-annual board meeting on July 8, 2017 in New York City. AXIM Biotech board members reviewed company milestones for the first half of 2017, clinical trial progress for irritable bowel syndrome (IBS), multiple sclerosis (MS) and psoriasis and eczema (PSO), the Company’s expanding product portfolio, and the current market opportunity for cannabinoid-based pharmaceuticals.   

Management and advisory board experts considered further proof of concept studies of cannabis based treatment for indications such as nicotine addiction, Glaucoma, dry eye syndrome, adolescent drug addiction, post-haerpetic neuralgia, traumatic brain injury (TBI), and ethyl alcohol abuse. Other items discussed during the board meeting included AXIM’s collaborations with leading academic institutions, strategic relationships with big-pharma manufacturers and distributors for drug development and licensing, as well as progress on vertical integration with the manufacturing facility in Almere, Netherlands.

“AXIM continues to make solid progress with our growth and positioning in the pharmaceutical space,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “There is a formidable opportunity for growth in pharmaceuticals based on cannabinoids and AXIM is executing on becoming a leader in this space with a robust clinical pipeline and expanded study for additional therapeutic indications. We are also excited to be embarking on clinical programs for new indications soon such as restless leg syndrome, chemotherapy associated N&V, drug-related psychosis and post-traumatic stress disorder (PTSD)."

About AXIM^®
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM^® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com

Investor Relations Contact
Shiwei Yin, Grayling
[email protected]
P. +1646 284-9474
Lucia Domville, Grayling
[email protected]
P. +1646 284-9416

Corporate Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227